Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Capricorn Pharma has signed an agreement with Teva Pharmaceuticals USA to develop products using its proprietary Korkoat technology platform.
Subscribe to our email newsletter
According to Capricorn, korkoat beads accommodate high drug loads; modified drug release can be achieved by incorporating release-modifying agents inside the bead, in the coating, or in both.
Rao Cherukuri, founder, president and CEO of Capricorn, said: “We are proud of our technologies, which offer flexible solutions to difficult formulation challenges. We believe this agreement further validates our commercialized oral drug delivery technology platforms and Capricorn’s proprietary encapsulation processes.”